Information  X 
Enter a valid email address

Zotefoams PLC (ZTF)

  Print      Mail a friend       Annual reports

Tuesday 08 October, 2019

Zotefoams PLC

Appointment of Joint Broker

RNS Number : 0276P
Zotefoams PLC
08 October 2019
 

 

Zotefoams plc

("Zotefoams" or "the Group")

 

Appointment of Joint Broker

 

 

 

08 October 2019 - Zotefoams, a world leader in cellular materials technology, today announces the appointment of Peel Hunt LLP to act as its joint broker alongside Investec Bank plc, with immediate effect.

 

-Ends-

 

 

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO


Gary McGrath, Group CFO




IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Zach Cohen


 

 

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology.  Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets.  In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).  A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPMRBJTMBJMBIL

a d v e r t i s e m e n t